非酒精性脂肪性肝炎的诊断和治疗进展

Recent advances in the diagnosis and treatment of nonalcoholic steatohepatitis

非酒精性脂肪肝疾病(nonalcoholic fatty liver disease,NAFLD)以肝细胞中脂肪过多积累为标志,包括非酒精性脂肪肝(nonalcoholic fatty liver,NAFL)和非酒精性脂肪性肝炎(nonalcoholic steatohepatitis,NASH),其中NASH可能会发展为肝硬化和肝细胞癌。目前除肝活检之外,并无有效的非侵入性诊断方法,也无精准治疗NASH的药物。因此,需要寻找合适的诊断标记和治疗靶点。随着近年的研究进展,NASH的发病机制愈渐清晰,联合多种生物标志物的预测模型也逐渐被采纳,许多针对新靶点的药物陆续进入有效性评估阶段。这使得NASH治疗的前景更加乐观。

Characterized with excessive accumulation of fat in liver cells,nonalcoholic fatty liver disease(NAFLD)is composed of nonalcoholic fatty liver(NAFL)and nonalcoholic steatohepatitis(NASH).As an inflammatory subtype of NAFLD,NASH may progress into cirrhosis and even hepatic tumor.However,there is currently no effective non-invasive diagnostic modality other than liver biopsy.And no approved drug is available for NASH.Thus it is imperative to seek suitable diagnostic biomarkers and effective therapeutic targets.With the progress of recent researches,scientists have acquired a deeper understanding of the pathogenic mechanism of NASH.Diagnostic models of multiple biomarkers have been put into trials.Many drug candidates against new targets have been evaluated for their effectiveness so that there is a brighter treatment prospect for NASH.